Bubiket Study: Ultrasound Guided Fascia Iliaca Nerve Block With Bupivacaine and Adjuvant Ketamine vs. Bupivacaine Alone

• Status: Withdrawn
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The project is meant to evaluate the effect of a combination of medications (Bupivacaine + Ketamine) used in an ultra-sound guided nerve block for patients presenting to the Emergency Department (ED) with hip and/or femur fractures. The goal is to see whether the combination of these two medications will result in greater and longer-lasting pain relief, longer-lasting motor and sensory block and overall less need for opioid rescue analgesia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Antonios Likourezos
• Treatments: Bupivacaine; Ketamine

Criteria

Inclusion Criteria:

• 18 years and older

• Presenting with isolated hip or femur fracture confirmed on x-ray.

Exclusion Criteria:

• Polytrauma

• Unstable vitals signs

• Allergy to Bupivacaine or Ketamine

• Inability to give consent

• Altered mental status

• Greater than 100kg

• Known end stage renal disease or hepatic dysfunction

• Received > 2 doses of Morphine in ER prior to regional nerve block

• Patients with failed nerve block (30 minute onset)